Heart Pump Devices Market Dynamics, Growth Segments by Opportunities, Future Demand Status and Business Advancement plans till 2027

Heart Pump Devices Market is expected to exceed the market valuation of more than US$ 6 billion by 2027 expanding at a reasonable CAGR of around 18.9% during the forecast period (2021-2027). Heart Pump Devices help the heart pump blood from the heart to different part of body. Heart pumps are made of material that allows the blood to be pumped through the blood vessels and ensures no coagulation takes place. The material should be biocompatible, otherwise the pump would not function properly. Additionally, considering possible chances of rejection, the device should be as compact as possible. There are two main types of heart pumps, pulsatile and rotary (continuous) blood pumps (axial and centrifugal). There are numerous continuous heart pumps in the market as compared to pulsatile heart pumps. The Pump sizes of these heart pumps can range from 25 to 1190 grams. Blood Pumps are required to perform at mean pressure of 100 and 20 mmHg for LVAD and RVAD respectively and the mean blood rate of 5L/min to support an adult at rest.

Download Free Sample of this Report - https://univdatos.com/request_form/form/444

A total of 25,145 adults received FDA approved MCSD in STS Intermacs between 2006 to 2017. Most of the devices i.e., 19,206 were CF LVADs. 667 of these also had a concomitant or secondary right VAD (RVAD) support. Out of all the patients 18.5% (4,656 patients) were required an additional LVAD due to the failure of the initial device that required replacement. Out of the remaining patients (74%), 14,527 patients received an axial flow LVAD, 3,853 received a mixed magnetic and hydrodynamic levitation centrifugal LVAD, and 159 received full magnetic levitation, centrifugal flow LVAD. The usage of magnetic levitation LVADs are expected to increase in the coming years. As of 2017, 51% centrifugal flow LVADs were used as compared to 49% axial flow devices.

Request for full report - https://univdatos.com/request_form/form/444

All industries have suffered some form of loss due to the pandemic. In addition to this the pandemic has also cost many lives. Till date there have been 177,470,620 covid-19 cases in the world and 3,839,931 deaths. A few studies have also reported other hidden symptoms of Covid-19 that can affect few individuals. The Coronavirus can cause cardiovascular conditions in individuals which can lead to the weakening of the biventricular function and leads to a higher mortality rate. In 4-50% of the cases, right ventricular failure can be a consequence of LAVD implantation. In a study from China, the mortality rate of LVAD patients was given 21.4%, on the other hand the general mortality rate was 2.3%. This huge variation in people with LVAD implants is a huge concern during covid-19. With a little relief of Covid-19, operational procedures are re-opening and people needing heart pumps or other implants can get them now. With the business going back to normal around the world, the heart pump market is expected to gain back its momentum in the market very fast.

Based on product, the heart pump devices market is segmented into ventricular assist devices (VADs), intra-aortic balloon pumps (IABPs) and total artificial heart (TAH). Ventricular assist devices are further segmented into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), bi-ventricular assist devices (BiVADs) and percutaneous ventricular assist devices (pVADs). The number of patients with heart failure is rising and because of that there is a shortage in organ donors. 43% of the patients between 2009 and 2016 were bridged with some type of heart pump device. In the United States between 2007 and 2017, 50% of the heart transplant patients were implanted with ventricular assist device.

Request To Download Sample of this Strategic Report - https://univdatos.com/request_form/form/444

Based on type, the heart pump devices market is bifurcated into implantable heart pump devices and extracorporeal heart pump devices. Implantable heart pump devices held the largest share in this segment. In an interview with the CEO of Corvion, it was stated that more number of people can benefit from heart pump devices than that are currently implanted. Currently only 10,000 LVADs are implanted per year whereas, there are potentially 100,000 to 300,000 patients who can benefit from these devices. The market is expected to grow as more devices get approved.

Based on therapy, the heart pump devices market is segmented into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination therapy (DT) and other therapies. Bridge-to-transplant therapies are used to support patient with heart failure, who are waiting for donor. This therapy allows the body systems to heal, rest and grow stronger before the actual transplant. Every year more than 5,000 people undergo heart transplants, however, the number of patients requiring a cardiac transplant goes up to 50,000 people, as of 2019. This number can be managed with the help of bridge-to-transplant and other heart pump devices.

Request for Sample of the report browse through - https://univdatos.com/request_form/form/444

Additionally, the report provides detailed initiatives that are being taken in the field of Heart Pump Devices, globally. The report provide a detailed analysis of regions including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), and the Rest of the World. North America dominated the market in 2020, with XX% share. Abbott Laboratories, Abiomed, Medtronic, Teleflex Incorporated, SynCardia Systems, Fresenius Medical Care AG & Co. KGaA, Getinge, CardiacAssist, Inc., Berlin Heart, and Jarvik Heart, Inc. are some of the prominent players operating in the global Heart Pump Devices market. Several M&As along with partnerships have been undertaken by these players to make Heart Pump Devicess as cost-effective and as widely available as possible.

Global Heart Pump Devices Market Segmentation

Market Insight, by Product

• Ventricular Assist Devices (VADs)
  • Left Ventricular Assist Devices (LVADs)
  • Right Ventricular Assist Devices (RVADs)
  • Bi-ventricular Assist Devices (BiVADs)
  • Percutaneous Ventricular Assist Devices (pVADs)
• Intra-Aortic Balloon Pumps (IABPs)
• Total Artificial Heart (TAH)

Market Insight, by Type

• Implantable Heart Pump Devices
• Extracorporeal Heart Pump Devices

Market Insight, by Therapy

• Bridge-To-Transplant (BTT)
• Bridge-To-Candidancy (BTC)
• Destination Therapy (DT)
• Other Therapies

Market Insight, by Region

• North America Heart Pump Devices Market
• United States
• Canada
• Rest of North America
• Europe Heart Pump Devices Market
• France
• Germany
• Italy
• Spain
• United Kingdom
• Rest of Europe
• Asia-Pacific Heart Pump Devices Market
• China
• Japan
• India
• Australia
• Rest of Asia-Pacific
• Rest of World Heart Pump Devices Market

Top Company Profiles

• Abbott Laboratories
• Abiomed
• Medtronic
• Teleflex Incorporated
• SynCardia Systems
• Fresenius Medical Care AG & Co. KGaA
• Getinge
• CardiacAssist, Inc.
• Berlin Heart
• Jarvik Heart, Inc.